Edition:
United States

Neuralstem Inc (CUR.PH)

CUR.PH on Philadelphia Stock Exchange

4.41USD
23 May 2017
Change (% chg)

-- (--)
Prev Close
$4.41
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
418
52-wk High
$6.08
52-wk Low
$2.59

Latest Key Developments (Source: Significant Developments)

Neuralstem reports last subject out in phase 2 trial of NSI-189 for major depressive disorder
Wednesday, 17 May 2017 04:05pm EDT 

May 17 (Reuters) - Neuralstem Inc :Neuralstem reports last subject out in phase 2 trial of NSI-189 for major depressive disorder.  Full Article

Neuralstem reports Q1 loss per share $0.68
Wednesday, 10 May 2017 04:05pm EDT 

May 10 (Reuters) - Neuralstem Inc :Neuralstem reports first quarter 2017 fiscal results provides clinical and business update.Q1 loss per share $0.68.Neuralstem - Expect existing cash, cash equivalents and short-term investments will fund anticipated level of operations into second half of 2018.  Full Article

Neuralstem says CFO leaves company
Thursday, 4 May 2017 04:02pm EDT 

May 4 (Reuters) - Neuralstem Inc :Neuralstem - on april 30, Jonathan Lloyd Jones, chief financial officer of Neuralstem, Inc. Left company to pursue other opportunities - sec filing.Neuralstem Inc - Richard Daly will serve as company's principal financial and accounting officer, on an interim basis.  Full Article

Neuralstem expands phase 1 safety trial of NSI-566 neural stem cells in spinal injury
Wednesday, 12 Apr 2017 07:35am EDT 

Neuralstem Inc : Neuralstem expands phase 1 safety trial of NSI-566 neural stem cells in spinal injury . Neuralstem - New cohort of four patients will be added to ongoing phase 1 human clinical trial for NSI-566 spinal cord-derived neural stem cells .Neuralstem - Amended protocol was approved by U.S. Food and Drug Administration, institutional review board at study site, University of California San Diego.  Full Article

Neuralstem reports year end 2016 fiscal results
Thursday, 23 Mar 2017 07:35am EDT 

Neuralstem Inc : Neuralstem reports year end 2016 fiscal results and business update . Neuralstem Inc - cash, cash equivalents, short-term investments on hand about $20.2 million at dec 31, 2016 versus about $12.2 million at december 31, 2015 .Neuralstem - expect existing cash, cash equivalents and short-term investments will fund anticipated level of operations into q2 of 2018.  Full Article

Neuralstem to continue as going concern is dependent on generating cash from the sale of its common stock
Thursday, 23 Mar 2017 07:15am EDT 

Neuralstem Inc : Neuralstem-Co's ability to continue as going concern is dependent on generating cash from the sale of its common stock and/or obtaining debt financing .Neuralstem-If co is not able to secure financing, co may be forced to delay/stop ongoing clinical trials, cease operations/file for bankruptcy.  Full Article

Tianjin Pharmaceuticals Group International Holdings reports 19.99 pct stake in Neuralstem - SEC Filing
Monday, 27 Feb 2017 03:39pm EST 

: Tianjin Pharmaceuticals Group International Holdings Co., Ltd reports 19.99 percent stake in Neuralstem Inc - SEC filing Source - (http://bit.ly/2l5LaeR) Further company coverage: [CUR.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Neuralstem says phase 2 data on NSI-189 expected ahead of schedule in Q3 2017
Thursday, 16 Feb 2017 07:02am EST 

Neuralstem Inc : Neuralstem announces last subject enrolled in phase 2 trial with NSI-189 for major depressive disorder .Neuralstem Inc - Phase 2 data now expected ahead of schedule in Q3 2017.  Full Article

Neuralstem reports third quarter 2016 results
Tuesday, 8 Nov 2016 07:35am EST 

Neuralstem Inc : Neuralstem reports third quarter 2016 results .Qtrly loss per share $0.05.  Full Article

Neuralstem says filed for a non-timely 10-Q - SEC filing
Tuesday, 9 Aug 2016 04:20pm EDT 

Neuralstem Inc : Says it has filed for a non-timely 10-Q - SEC filing . Says unable to file quarterly report on form 10-Q for period ended June 30, 2016 due to difficulty in obtaining required information Source: (http://bit.ly/2b0Z3SN ) Further company coverage: [CUR.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

More From Around the Web

BRIEF-Neuralstem reports last subject out in phase 2 trial of NSI-189 for major depressive disorder

* Neuralstem reports last subject out in phase 2 trial of NSI-189 for major depressive disorder Source text for Eikon: Further company coverage: